How to provide Process Validation Data in a Regulatory Submission

How to provide Process Validation Data in a Regulatory Submission

Berlin, Germany

Course No 15878


Costs

Non-ECA Members: EUR 1790,--
ECA Members: EUR 1590,--
EU GMP Inspectorates: EUR 895,--
APIC Members (does not include ECA membership): EUR 1690,--

(All prices excl. VAT)

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: info@gmp-compliance.org

Speakers

Dr Hiltrud Horn, Horn Pharmaceutical Consulting, Germany

Dr Wilhelm Schlumbohm, Berlin, Germany

Dr Norbert Skuballa, Biologische Arzneimittel Heel, Germany

Objectives

This education course focuses on how to compile and provide information and data from process validations for Drug Substances and Drug Products both of chemical and biotechnological origin. You will learn

  • How to prepare and process the data derived from validation runs of drug product manufacturing processes
  • What needs to be documented about drug substance manufacturing processes
  • How to manage and document post approval changes in manufacturing processes
  • What to consider for compiling stability data for the dossier
  • How to provide validation data of biotech manufacturing processes

Background

Process validation can be defined as documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce a medicinal product meeting its predetermined specifications and quality attributes. In general there are two options to validate a manufacturing process: a traditional approach or an enhanced approach where continuous process verification is applied. Irrespective of which approach is used the manufacturing process should be validated before the product is placed on the market. Therefore complete data have to be provided in the dossier at the time of regulatory submission. These data should cover the validation for all manufactured strengths, batch sizes, pack sizes and proposed manufacturing sites.

Guidance on process validation information to be provided in regulatory submissions is given in 2 EMA Guidelines: “Guideline on process validation for finished products – information and data to be provided in regulatory submissions” and “Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission”. Provisions of both GMP compliant manufacture and dossier requirements are laid down in FDA’s Guidance for Industry entitled “Process Validation: General Principles and Practices”.

Target Group

This education course is designed for all persons involved in the compilation of dossiers for regulatory submissions who want to become familiar with the requirements for the documentation of process validation data. The course will be of interest in particular for personnel from Regulatory Affairs as well as for personnel from Quality Assurance, Production and Quality Control.

Programme

Process validation of manufacturing processes – Dossier requirements in the EU

  • Relevant guidance documents
  • Finished product process validation
  • Traditional and enhanced approaches
  • Process validation schemes
  • Standard vs. non-standard processes
Traditional Process Validation and Continuous Process Verification
  • What are the opportunities and challenges?
  • What are the key aspects for the CTD?
  • What should you consider for selecting the right validation strategy?
  • What should you know about design space?
  • What are typical validation questions to be addressed?
How to provide stability data in regulatory submissions
  • Stability data from drug substances and drug products in the CTD
  • Long term and accelerated conditions, in-use stability
  • Requirements for the different climatic zones
  • Stability summary and conclusion
  • Process parameters with potential impact on drug substance/drug product stability
  • Changes in the process: what has to be considered regarding stability?
Manufacture of active substances – Process validation and GMP issues
  • API manufacture – What needs to be documented in the dossier?
  • Process validation for APIs – Key aspects
  • GMP for APIs
Case Studies on typical Validation Projects
  • Standard and non-standard processes
  • Validation approach for drug substances and drug products
  • Validation strategy and planning from development to registration
  • Specific points to be considered for EU and US
Basic requirements and expectations of the FDA regarding process validation
  • Approach to and considerations for process validation
  • Process Design
  • Process qualification and process performance qualification (PPQ)
  • The PPQ protocol – execution and report
Handling Post-Approval Changes in manufacturing processes
  • Which GMP and regulatory aspects need to be considered (e.g. site /process changes)?
  • How to define the validation strategy?
  • What are the challenges?
  • How to be successful?
Process validation for the manufacture of biotech-derived APIs – process evaluation and verification
  • Process evaluation
  • Critical quality attributes (CQAs) of the active substance
  • Small scale models
  • Process verification studies and data
  • Number of batches to be presented
  • Design space option
  • Evaluation of the upstream process
  • Criticality assignment of process parameters
  • Potential impact of raw materials
  • Verification of upstream process
  • Single use equipment
  • Evaluation and verification of downstream process
  • Comparability of products manufactured in different sites

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK